Hookipa Pharma Gets $5 Million Milestone Payment From Gilead Sciences
January 04 2023 - 07:53AM
Dow Jones News
By Chris Wack
Hookipa Pharma Inc. said Wednesday that it has achieved a $5
million non-dilutive milestone payment under its collaboration
agreement with Gilead Sciences Inc.
The company said it completed and delivered a regulatory support
package for Gilead's Phase 1 clinical trial of an investigational
therapeutic vaccine for chronic hepatitis B using Hookipa's
arenaviral platform.
Gilead is solely responsible for further development and
commercialization of the hepatitis B product candidate. Hookipa is
eligible to receive milestone payments based on the achievement of
specified development, regulatory and commercial milestones up to a
total of more than $190 million, and is also eligible to receive
tiered royalties on net sales.
Hookipa shares were up 7% at 86 cents a share in premarket
trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 04, 2023 07:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Feb 2023 to Mar 2023
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2022 to Mar 2023
